Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

PLC Systems announced a three year exclusive agreement with Medimen for distribution of its RenalGuard System into Bangladesh and Pakistan

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, announced that it has entered into a three year exclusive agreement with Medimen (Pvt.) Ltd., headquartered in Pakistan, for distribution of its RenalGuard System into Bangladesh and Pakistan. Medimen is an established distributor of medical technology and devices in this region, and has previously worked with PLC on distribution of the Heart Laser System. Medimen has already launched RenalGuard in Bangladesh, and will target early adopters in both countries who recognize the benefits of utilizing the unique fluid balancing capabilities of RenalGuard(R) in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of Contrast-Induced Nephropathy (CIN).

PLC's President and Chief Executive Officer, Mark R. Tauscher, said, "We are very pleased to extend the launch of our RenalGuard technology to another region of the world, working with our partners at Medimen. We believe Medimen's efforts will help raise awareness of the benefits of RenalGuard to a wider community of physicians in both Bangladesh and Pakistan."

Bangladesh and Pakistan join Italy and Spain as countries where PLC has now launched RenalGuard. PLC received the CE Mark Certificate for the RenalGuard System in late December 2007, and concluded its pilot safety trial in the U.S. late in 2007. Two investigator-sponsored randomized clinical trials to evaluate the use of RenalGuard in the prevention of CIN are currently underway in Italy. Recently, PLC was awarded its first patent for RenalGuard technology, in Canada.

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO(2) Heart Laser System, which cardiac surgeons use to perform CO(2) transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

Source: PLC Systems